Sipuleucel-T
- TRADE NAME: Provenge (Dendreon)
- INDICATIONS: Treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer
- CLASS: Vaccine
- HALF-LIFE: N/A
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Abatacept, Alefacept, Azacitidine, Betamethasone, Cabazitaxel, Denileukin, Docetaxel, Fingolimod, Gefitinib, Lenalidomide, Oxaliplatin, Pazopanib, Pemetrexed, Pralatrexate, Triamcinolone
PREGNANCY CATEGORY: N/A
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
Page last updated 08/01/2022
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
